ometendoОжирение и метаболизмObesity and metabolism2071-87132306-5524Endocrinology Research Centre10.14341/omet9986ometendo-9986Research ArticleОбзор литературыReviewВзгляд на новые терапевтические возможности у больных с неалкогольной жировой болезнью печениA look at new therapeutic opportunities in patients with non-alcoholic fatty liver diseasehttps://orcid.org/0000-0002-5371-8708МишинаЕкатерина ЕвгеньевнаMishinaEkaterina E.

аспирант, научный сотрудник

MD, PhDstudent, research associate

Eka-mi@rambler.ruhttps://orcid.org/0000-0001-9453-8212МайоровАлександр ЮрьевичMayorovAlexander Y.

д.м.н.

MD, PhD

education@endocrincentr.ruhttps://orcid.org/0000-0002-8664-6341БоголюбоваАполлинария ВасильевнаBogolyubovaApollinariya V.

младший научный сотрудник лаборатории передачи внутриклеточных сигналов в норме и патологии

junior research associate

apollinariya.bogolyubova@gmail.comhttps://orcid.org/0000-0003-2346-1216БогомоловПавел ОлеговичBogomolovPavel O.

руководитель отдела гепатологии

MD, PhD

bpo73@list.ruhttps://orcid.org/0000-0002-1292-4409МациевичМария ВладиславовнаMatsievichMaria V.

старший научный сотрудник

MD, PhD

macievich@gmail.comhttps://orcid.org/0000-0003-4864-1483КокинаКсения ЮрьевнаKokinaKsenia Y.

научный сотрудник

MD

sucliks@gmail.comФГБУ «Национальный медицинский исследовательский центр эндокринологии» Минздрава РоссииРоссияEndocrinology Research CentreRussian FederationФГБУН «Институт молекулярной биологии им. В.А. Энгельгардта» Российской академии наукРоссияEngelhardt Institute of Molecular Biology of the Russian Academy of SciencesRussian FederationГБУЗ МО «Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского»РоссияM.F. Vladimirskiy Moscow Regional Research and Clinical InstituteRussian Federation2019211220191633745Copyright © Мишина Е.Е., Майоров А.Ю., Боголюбова А.В., Богомолов П.О., Мациевич М.В., Кокина К.Ю., 20192019Мишина Е.Е., Майоров А.Ю., Боголюбова А.В., Богомолов П.О., Мациевич М.В., Кокина К.Ю.Mishina E.E., Mayorov A.Y., Bogolyubova A.V., Bogomolov P.O., Matsievich M.V., Kokina K.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.omet-endojournals.ru/jour/article/view/9986

Неалкогольная жировая болезнь печени (НАЖБП) является самым распространенным заболеванием печени повсеместно и считается печеночной манифестацией метаболического синдрома. В настоящее время не существует средств этиотропной терапии НАЖБП, ввиду чего ведется активный поиск новых методов лечения. А пока используются препараты для лечения коморбидных состояний, таких как дислипидемия, артериальная гипертензия, ожирение, сахарный диабет 2 типа, которые в той или иной степени присутствуют у пациентов. В данном обзоре рассмотрены препараты, которые применяются у пациентов с НАЖБП и сопутствующими коморбидными состояниями, а также рассмотрены новые стратегии регресса изменений в печеночной ткани при НАЖБП. На наш взгляд, одной из перспективных групп лекарственных препаратов являются агонисты фарнезоидного Х-рецептора (FXR). FXR относится к группе ядерных рецепторов, являющихся лиганд-активируемыми транскрипционными факторами, которые регулируют гены, вовлеченные в метаболизм. Таким образом, оказывая влияние на углеводный, жировой обмены, обмен желчных кислот, а также на воспалительные процессы в печени для обеспечения метаболического гомеостаза, агонисты FXR могут претендовать на роль нового многообещающего препарата для лечения НАЖБП и коморбидных состояний.

Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide, and is considered to be the liver manifestation of metabolic syndrome. Currently, there is no etiotropic treatment of NAFLD, so an active research for new methods of treatment is underway. In the meantime, drugs are used to treat comorbid conditions, such as dyslipidemia, arterial hypertension, obesity, type 2 diabetes, which are present in varying degrees in patients. This review considers medications that are used in patients with NAFLD and related concomitant features, and also describes new strategies for regressing changes in liver tissue in NAFLD. In our opinion, one of the promising groups of drugs are agonists of the farnesoid X receptor (FXR). FXR belongs to the group of nuclear receptors, which are ligand-activated transcription factors that regulate the genes involved in metabolism. FXR agonists can claim to be a new promising drug for the treatment of NAFLD and related diseases influencing carbohydrate metabolism, fat metabolism, bile acid metabolism, as well as inflammatory processes in the liver to ensure metabolic homeostasis.

неалкогольная жировая болезнь печенисахарный диабетинсулинорезистентностьагонисты фарнезоидного Х-рецептора (FXR)неалкогольный стеатогепатитожирениеinsulin resistancediabetes mellitusnonalcoholic fatty liver diseasefarnesoid X receptor (FXR)nonalcoholic steatohepatitisobesityОбзор литературы подготовлен в рамках реализации научной программы, поддержанной грантом Российского научного фонда (проект №17-15-01475).A literature review was prepared as part of the implementation of a scientific program supported by a grant from the Russian Science Foundation (project No. 17-15-01475).ReferencesYounossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84. DOI:10.1002/hep.28431Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84. DOI:10.1002/hep.28431Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic Steatohepatitis Is the Second Leading Etiology of Liver Disease Among Adults Awaiting Liver Transplantation in the United States. Gastroenterology. 2015;148(3):547-555. DOI:10.1053/j.gastro.2014.11.039Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic Steatohepatitis Is the Second Leading Etiology of Liver Disease Among Adults Awaiting Liver Transplantation in the United States. Gastroenterology. 2015;148(3):547-555. DOI:10.1053/j.gastro.2014.11.039Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-357. DOI:10.1002/hep.29367Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-357. DOI:10.1002/hep.29367Oseini AM, Sanyal AJ. Therapies in non-alcoholic steatohepatitis (NASH). Liver Int. 2017;37(1):97-103. DOI:10.1111/liv.13302Oseini AM, Sanyal AJ. Therapies in non-alcoholic steatohepatitis (NASH). Liver Int. 2017;37(1):97-103. DOI:10.1111/liv.13302Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites. Hepatology. 2010;52(2):774-788. DOI:10.1002/hep.23719Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites. Hepatology. 2010;52(2):774-788. DOI:10.1002/hep.23719Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology. 2015;149(2):367-378.e5. DOI:10.1053/j.gastro.2015.04.005Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology. 2015;149(2):367-378.e5. DOI:10.1053/j.gastro.2015.04.005Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2015;149(2):389-397.e10. DOI:10.1053/j.gastro.2015.04.043Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2015;149(2):389-397.e10. DOI:10.1053/j.gastro.2015.04.043Tziomalos K, Athyros VG, Paschos P, Karagiannis A. Nonalcoholic fatty liver disease and statins. Metabolism. 2015;64(10):1215-1223. DOI:10.1016/j.metabol.2015.07.003Tziomalos K, Athyros VG, Paschos P, Karagiannis A. Nonalcoholic fatty liver disease and statins. Metabolism. 2015;64(10):1215-1223. DOI:10.1016/j.metabol.2015.07.003Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology. 2010;52(1):79-104. DOI:10.1002/hep.23623Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology. 2010;52(1):79-104. DOI:10.1002/hep.23623Jain MR, Giri SR, Bhoi B, et al. Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models. Liver Int. 2018;38(6):1084-1094. DOI:10.1111/liv.13634Jain MR, Giri SR, Bhoi B, et al. Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models. Liver Int. 2018;38(6):1084-1094. DOI:10.1111/liv.13634Chatterjee S, Majumder A, Ray S. Observational Study of Effects of Saroglitazar on Glycaemic and Lipid Parameters on Indian Patients with Type 2 Diabetes. Sci Rep. 2015;5(1):7706. DOI:10.1038/srep07706Chatterjee S, Majumder A, Ray S. Observational Study of Effects of Saroglitazar on Glycaemic and Lipid Parameters on Indian Patients with Type 2 Diabetes. Sci Rep. 2015;5(1):7706. DOI:10.1038/srep07706Watanabe K, Ueno M, Kamiya D, et al. A ROCK inhibitor permits survival of dissociated human embryonic stem cells. Nat Biotechnol. 2007;25(6):681-686. DOI:10.1038/nbt1310Watanabe K, Ueno M, Kamiya D, et al. A ROCK inhibitor permits survival of dissociated human embryonic stem cells. Nat Biotechnol. 2007;25(6):681-686. DOI:10.1038/nbt1310Dasarathy S, Dasarathy J, Khiyami A, et al. Double-blind Randomized Placebo-controlled Clinical Trial of Omega 3 Fatty Acids for the Treatment of Diabetic Patients With Nonalcoholic Steatohepatitis. J Clin Gastroenterol. 2015;49(2):137-144. DOI:10.1097/MCG.0000000000000099Dasarathy S, Dasarathy J, Khiyami A, et al. Double-blind Randomized Placebo-controlled Clinical Trial of Omega 3 Fatty Acids for the Treatment of Diabetic Patients With Nonalcoholic Steatohepatitis. J Clin Gastroenterol. 2015;49(2):137-144. DOI:10.1097/MCG.0000000000000099Byrne CD, Targher G. NAFLD: A multisystem disease. J Hepatol. 2015;62(1):S47-S64. DOI:10.1016/j.jhep.2014.12.012Byrne CD, Targher G. NAFLD: A multisystem disease. J Hepatol. 2015;62(1):S47-S64. DOI:10.1016/j.jhep.2014.12.012Sumida Y, Seko Y, Yoneda M. Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus. Hepatol Res. 2017;47(4):266-280. DOI:10.1111/hepr.12856Sumida Y, Seko Y, Yoneda M. Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus. Hepatol Res. 2017;47(4):266-280. DOI:10.1111/hepr.12856Ding X, Saxena NK, Lin S, Gupta N, Anania FA. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis inob/ob mice. Hepatology. 2006;43(1):173-181. DOI:10.1002/hep.21006Ding X, Saxena NK, Lin S, Gupta N, Anania FA. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis inob/ob mice. Hepatology. 2006;43(1):173-181. DOI:10.1002/hep.21006Mells JE, Fu PP, Sharma S, et al. Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet. Am J Physiol Liver Physiol. 2012;302(2):G225-G235. DOI:10.1152/ajpgi.00274.2011Mells JE, Fu PP, Sharma S, et al. Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet. Am J Physiol Liver Physiol. 2012;302(2):G225-G235. DOI:10.1152/ajpgi.00274.2011Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387(10019):679-690. DOI:10.1016/S0140-6736(15)00803-XArmstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387(10019):679-690. DOI:10.1016/S0140-6736(15)00803-XMarso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834-1844. DOI:10.1056/NEJMoa1607141Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834-1844. DOI:10.1056/NEJMoa1607141Jones B. Liraglutide and cardiovascular outcomes in type 2 diabetes. Ann Clin Biochem. 2016;53(6):712-712. DOI:10.1177/0004563216663075Jones B. Liraglutide and cardiovascular outcomes in type 2 diabetes. Ann Clin Biochem. 2016;53(6):712-712. DOI:10.1177/0004563216663075Joy TR, McKenzie CA, Tirona RG, et al. Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial. World J Gastroenterol. 2017;23(1):141. DOI:10.3748/wjg.v23.i1.141Joy TR, McKenzie CA, Tirona RG, et al. Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial. World J Gastroenterol. 2017;23(1):141. DOI:10.3748/wjg.v23.i1.141Yilmaz Y, Yonal O, Deyneli O, et al. Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis. Acta Gastroenterol Belg. 2012;75(2):240-244. PMID: 22870790Yilmaz Y, Yonal O, Deyneli O, et al. Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis. Acta Gastroenterol Belg. 2012;75(2):240-244. PMID: 22870790Fitchett D, Zinman B, Wanner C, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME ® trial. Eur Heart J. 2016;37(19):1526-1534. DOI:10.1093/eurheartj/ehv728Fitchett D, Zinman B, Wanner C, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME ® trial. Eur Heart J. 2016;37(19):1526-1534. DOI:10.1093/eurheartj/ehv728Qiang S, Nakatsu Y, Seno Y, et al. Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus. Diabetol Metab Syndr. 2015;7(1):104. DOI:10.1186/s13098-015-0102-8Qiang S, Nakatsu Y, Seno Y, et al. Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus. Diabetol Metab Syndr. 2015;7(1):104. DOI:10.1186/s13098-015-0102-8Honda Y, Imajo K, Kato T, et al. The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice. PLoS One. 2016;11(1):e0146337. DOI:10.1371/journal.pone.0146337Honda Y, Imajo K, Kato T, et al. The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice. PLoS One. 2016;11(1):e0146337. DOI:10.1371/journal.pone.0146337Gautam A, Agrawal PK, Doneria J, Nigam A. Effects of Canagliflozin on Abnormal Liver Function Tests in Patients of Type 2 Diabetes with Non-Alcoholic Fatty Liver Disease. J Assoc Physicians India. 2018;66(8):62-66. PMID: 31324087Gautam A, Agrawal PK, Doneria J, Nigam A. Effects of Canagliflozin on Abnormal Liver Function Tests in Patients of Type 2 Diabetes with Non-Alcoholic Fatty Liver Disease. J Assoc Physicians India. 2018;66(8):62-66. PMID: 31324087Boettcher E, Csako G, Pucino F, et al. Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2012;35(1):66-75. DOI:10.1111/j.1365-2036.2011.04912.xBoettcher E, Csako G, Pucino F, et al. Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2012;35(1):66-75. DOI:10.1111/j.1365-2036.2011.04912.xLincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and Risk of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus. JAMA. 2007;298(10):1180. DOI:10.1001/jama.298.10.1180Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and Risk of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus. JAMA. 2007;298(10):1180. DOI:10.1001/jama.298.10.1180Chalasani NP, Sanyal AJ, Kowdley KV., et al. Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials. 2009;30(1):88-96. DOI:10.1016/j.cct.2008.09.003Chalasani NP, Sanyal AJ, Kowdley KV., et al. Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials. 2009;30(1):88-96. DOI:10.1016/j.cct.2008.09.003Mahady SE, Webster AC, Walker S, et al. The role of thiazolidinediones in non-alcoholic steatohepatitis – A systematic review and meta analysis.. J Hepatol. 2011;55(6):1383-1390. DOI:10.1016/j.jhep.2011.03.016Mahady SE, Webster AC, Walker S, et al. The role of thiazolidinediones in non-alcoholic steatohepatitis – A systematic review and meta analysis.. J Hepatol. 2011;55(6):1383-1390. DOI:10.1016/j.jhep.2011.03.016Piccinni C, Motola D, Marchesini G, Poluzzi E. Assessing the Association of Pioglitazone Use and Bladder Cancer Through Drug Adverse Event Reporting. Diabetes Care. 2011;34(6):1369-1371. DOI:10.2337/dc10-2412Piccinni C, Motola D, Marchesini G, Poluzzi E. Assessing the Association of Pioglitazone Use and Bladder Cancer Through Drug Adverse Event Reporting. Diabetes Care. 2011;34(6):1369-1371. DOI:10.2337/dc10-2412Tuccori M, Filion KB, Yin H, et al. Pioglitazone use and risk of bladder cancer: population based cohort study. BMJ. 2016;34(6):i1541. DOI:10.1136/bmj.i1541Tuccori M, Filion KB, Yin H, et al. Pioglitazone use and risk of bladder cancer: population based cohort study. BMJ. 2016;34(6):i1541. DOI:10.1136/bmj.i1541Lecka-Czernik B. Bone Loss in Diabetes: Use of Antidiabetic Thiazolidinediones and Secondary Osteoporosis. Curr Osteoporos Rep. 2010;8(4):178-184. DOI:10.1007/s11914-010-0027-yLecka-Czernik B. Bone Loss in Diabetes: Use of Antidiabetic Thiazolidinediones and Secondary Osteoporosis. Curr Osteoporos Rep. 2010;8(4):178-184. DOI:10.1007/s11914-010-0027-yEASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388-1402. DOI:10.1016/j.jhep.2015.11.004EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388-1402. DOI:10.1016/j.jhep.2015.11.004Chan JM, Darke AK, Penney KL, et al. Selenium- or Vitamin E-Related Gene Variants, Interaction with Supplementation, and Risk of High-Grade Prostate Cancer in SELECT. Cancer Epidemiol Biomarkers Prev. 2016;25(7):1050-1058. DOI:10.1158/1055-9965.EPI-16-0104Chan JM, Darke AK, Penney KL, et al. Selenium- or Vitamin E-Related Gene Variants, Interaction with Supplementation, and Risk of High-Grade Prostate Cancer in SELECT. Cancer Epidemiol Biomarkers Prev. 2016;25(7):1050-1058. DOI:10.1158/1055-9965.EPI-16-0104Schurks M, Glynn RJ, Rist PM, et al. Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials. BMJ. 2010;341:c5702. DOI:10.1136/bmj.c5702Schurks M, Glynn RJ, Rist PM, et al. Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials. BMJ. 2010;341:c5702. DOI:10.1136/bmj.c5702Staels B, Rubenstrunk A, Noel B, et al. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology. 2013;58(6):1941-1952. DOI:10.1002/hep.26461Staels B, Rubenstrunk A, Noel B, et al. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology. 2013;58(6):1941-1952. DOI:10.1002/hep.26461Newsome PN. Entering the GOLDEN Age for Therapies in NASH. Gastroenterology. 2016;150(5):1073-1076. DOI:10.1053/j.gastro.2016.03.014Newsome PN. Entering the GOLDEN Age for Therapies in NASH. Gastroenterology. 2016;150(5):1073-1076. DOI:10.1053/j.gastro.2016.03.014Colca JR, VanderLugt JT, Adams WJ, et al. Clinical Proof-of-Concept Study With MSDC-0160, a Prototype mTOT-Modulating Insulin Sensitizer. Clin Pharmacol Ther. 2013;93(4):352-359. DOI:10.1038/clpt.2013.10Colca JR, VanderLugt JT, Adams WJ, et al. Clinical Proof-of-Concept Study With MSDC-0160, a Prototype mTOT-Modulating Insulin Sensitizer. Clin Pharmacol Ther. 2013;93(4):352-359. DOI:10.1038/clpt.2013.10McCommis KS, Hodges WT, Brunt EM, et al. Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitis. Hepatology. 2017;65(5):1543-1556. DOI:10.1002/hep.29025McCommis KS, Hodges WT, Brunt EM, et al. Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitis. Hepatology. 2017;65(5):1543-1556. DOI:10.1002/hep.29025Townsend SA, Newsome PN. Review article: new treatments in non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2017;46(5):494-507. DOI:10.1111/apt.14210Townsend SA, Newsome PN. Review article: new treatments in non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2017;46(5):494-507. DOI:10.1111/apt.14210Tacke F. Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis. Expert Opin Investig Drugs. 2018;27(3):301-311. DOI:10.1080/13543784.2018.1442436Tacke F. Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis. Expert Opin Investig Drugs. 2018;27(3):301-311. DOI:10.1080/13543784.2018.1442436Friedman S, Sanyal A, Goodman Z, et al. Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design. Contemp Clin Trials. 2016;47(3):356-365. DOI:10.1016/j.cct.2016.02.012Friedman S, Sanyal A, Goodman Z, et al. Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design. Contemp Clin Trials. 2016;47(3):356-365. DOI:10.1016/j.cct.2016.02.012Barreyro FJ, Holod S, Finocchietto P V., et al. The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis. Liver Int. 2015;35(3):953-966. DOI:10.1111/liv.12570Barreyro FJ, Holod S, Finocchietto P V., et al. The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis. Liver Int. 2015;35(3):953-966. DOI:10.1111/liv.12570Safadi R, Konikoff FM, Mahamid M, et al. The Fatty Acid–Bile Acid Conjugate Aramchol Reduces Liver Fat Content in Patients With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2014;12(12):2085-2091.e1. DOI:10.1016/j.cgh.2014.04.038Safadi R, Konikoff FM, Mahamid M, et al. The Fatty Acid–Bile Acid Conjugate Aramchol Reduces Liver Fat Content in Patients With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2014;12(12):2085-2091.e1. DOI:10.1016/j.cgh.2014.04.038Ekstedt M, Hagström H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61(5):1547-1554. DOI:10.1002/hep.27368Ekstedt M, Hagström H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61(5):1547-1554. DOI:10.1002/hep.27368Barry-Hamilton V, Spangler R, Marshall D, et al. Allosteric inhibition of lysyl oxidase–like-2 impedes the development of a pathologic microenvironment. Nat Med. 2010;16(9):1009-1017. DOI:10.1038/nm.2208Barry-Hamilton V, Spangler R, Marshall D, et al. Allosteric inhibition of lysyl oxidase–like-2 impedes the development of a pathologic microenvironment. Nat Med. 2010;16(9):1009-1017. DOI:10.1038/nm.2208Harrison SA, Abdelmalek MF, Caldwell S, et al. Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis. Gastroenterology. 2018;155(4):1140-1153. DOI:10.1053/j.gastro.2018.07.006Harrison SA, Abdelmalek MF, Caldwell S, et al. Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis. Gastroenterology. 2018;155(4):1140-1153. DOI:10.1053/j.gastro.2018.07.006Budas G, Karnik S, Jonnson T, et al. Reduction of Liver Steatosis and Fibrosis with an Ask1 Inhibitor in a Murine Model of Nash is Accompanied by Improvements in Cholesterol, Bile Acid and Lipid Metabolism. J Hepatol. 2016;64(2):S170. DOI:10.1016/S0168-8278(16)01686-XBudas G, Karnik S, Jonnson T, et al. Reduction of Liver Steatosis and Fibrosis with an Ask1 Inhibitor in a Murine Model of Nash is Accompanied by Improvements in Cholesterol, Bile Acid and Lipid Metabolism. J Hepatol. 2016;64(2):S170. DOI:10.1016/S0168-8278(16)01686-XLoomba R, Lawitz E, Mantry PS, et al. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial. Hepatology. 2018;67(2):549-559. DOI:10.1002/hep.29514Loomba R, Lawitz E, Mantry PS, et al. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial. Hepatology. 2018;67(2):549-559. DOI:10.1002/hep.29514Compare D, Coccoli P, Rocco A, et al. Gut–liver axis: The impact of gut microbiota on non alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 2012;22(6):471-476. DOI:10.1016/j.numecd.2012.02.007Compare D, Coccoli P, Rocco A, et al. Gut–liver axis: The impact of gut microbiota on non alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 2012;22(6):471-476. DOI:10.1016/j.numecd.2012.02.007Kim S-G, Kim B-K, Kim K, Fang S. Bile Acid Nuclear Receptor Farnesoid X Receptor: Therapeutic Target for Nonalcoholic Fatty Liver Disease. Endocrinol Metab. 2016;31(4):500. DOI:10.3803/EnM.2016.31.4.500Kim S-G, Kim B-K, Kim K, Fang S. Bile Acid Nuclear Receptor Farnesoid X Receptor: Therapeutic Target for Nonalcoholic Fatty Liver Disease. Endocrinol Metab. 2016;31(4):500. DOI:10.3803/EnM.2016.31.4.500Makishima M. Identification of a Nuclear Receptor for Bile Acids. Science (80- ). 1999;284(5418):1362-1365. DOI:10.1126/science.284.5418.1362Makishima M. Identification of a Nuclear Receptor for Bile Acids. Science (80- ). 1999;284(5418):1362-1365. DOI:10.1126/science.284.5418.1362Chiang JYL. Bile Acid Regulation of Gene Expression: Roles of Nuclear Hormone Receptors. Endocr Rev. 2002;23(4):443-463. DOI:10.1210/er.2000-0035Chiang JYL. Bile Acid Regulation of Gene Expression: Roles of Nuclear Hormone Receptors. Endocr Rev. 2002;23(4):443-463. DOI:10.1210/er.2000-0035Allen K, Jaeschke H, Copple BL. Bile Acids Induce Inflammatory Genes in Hepatocytes. Am J Pathol. 2011;178(1):175-186. DOI:10.1016/j.ajpath.2010.11.026Allen K, Jaeschke H, Copple BL. Bile Acids Induce Inflammatory Genes in Hepatocytes. Am J Pathol. 2011;178(1):175-186. DOI:10.1016/j.ajpath.2010.11.026Claudel T, Staels B, Kuipers F. The Farnesoid X Receptor. Arterioscler Thromb Vasc Biol. 2005;25(10):2020-2030. DOI:10.1161/01.ATV.0000178994.21828.a7Claudel T, Staels B, Kuipers F. The Farnesoid X Receptor. Arterioscler Thromb Vasc Biol. 2005;25(10):2020-2030. DOI:10.1161/01.ATV.0000178994.21828.a7De Fabiani E, Mitro N, Gilardi F, Caruso D, Galli G, Crestani M. Coordinated Control of Cholesterol Catabolism to Bile Acids and of Gluconeogenesis via a Novel Mechanism of Transcription Regulation Linked to the Fasted-to-fed Cycle. J Biol Chem. 2003;278(40):39124-39132. DOI:10.1074/jbc.M305079200De Fabiani E, Mitro N, Gilardi F, Caruso D, Galli G, Crestani M. Coordinated Control of Cholesterol Catabolism to Bile Acids and of Gluconeogenesis via a Novel Mechanism of Transcription Regulation Linked to the Fasted-to-fed Cycle. J Biol Chem. 2003;278(40):39124-39132. DOI:10.1074/jbc.M305079200Stayrook KR, Bramlett KS, Savkur RS, et al. Regulation of Carbohydrate Metabolism by the Farnesoid X Receptor. Endocrinology. 2005;146(3):984-991. DOI:10.1210/en.2004-0965Stayrook KR, Bramlett KS, Savkur RS, et al. Regulation of Carbohydrate Metabolism by the Farnesoid X Receptor. Endocrinology. 2005;146(3):984-991. DOI:10.1210/en.2004-0965Ma K. Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest. 2006;116(4):1102-1109. DOI:10.1172/JCI25604Ma K. Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest. 2006;116(4):1102-1109. DOI:10.1172/JCI25604Duran-Sandoval D, Mautino G, Martin G, et al. Glucose Regulates the Expression of the Farnesoid X Receptor in Liver. Diabetes. 2004;53(4):890-898. DOI:10.2337/diabetes.53.4.890Duran-Sandoval D, Mautino G, Martin G, et al. Glucose Regulates the Expression of the Farnesoid X Receptor in Liver. Diabetes. 2004;53(4):890-898. DOI:10.2337/diabetes.53.4.890Zhang Y, Lee FY, Barrera G, et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci. 2006;103(4):1006-1011. DOI:10.1073/pnas.0506982103Zhang Y, Lee FY, Barrera G, et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci. 2006;103(4):1006-1011. DOI:10.1073/pnas.0506982103Cariou B, van Harmelen K, Duran-Sandoval D, et al. The Farnesoid X Receptor Modulates Adiposity and Peripheral Insulin Sensitivity in Mice. J Biol Chem. 2006;281(16):11039-11049. DOI:10.1074/jbc.M510258200Cariou B, van Harmelen K, Duran-Sandoval D, et al. The Farnesoid X Receptor Modulates Adiposity and Peripheral Insulin Sensitivity in Mice. J Biol Chem. 2006;281(16):11039-11049. DOI:10.1074/jbc.M510258200Jiao Y, Lu Y, Li X. Farnesoid X receptor: a master regulator of hepatic triglyceride and glucose homeostasis. Acta Pharmacol Sin. 2015;36(1):44-50. DOI:10.1038/aps.2014.116Jiao Y, Lu Y, Li X. Farnesoid X receptor: a master regulator of hepatic triglyceride and glucose homeostasis. Acta Pharmacol Sin. 2015;36(1):44-50. DOI:10.1038/aps.2014.116Cyphert HA, Ge X, Kohan AB, et al. Activation of the Farnesoid X Receptor Induces Hepatic Expression and Secretion of Fibroblast Growth Factor 21. J Biol Chem. 2012;287(30):25123-25138. DOI:10.1074/jbc.M112.375907Cyphert HA, Ge X, Kohan AB, et al. Activation of the Farnesoid X Receptor Induces Hepatic Expression and Secretion of Fibroblast Growth Factor 21. J Biol Chem. 2012;287(30):25123-25138. DOI:10.1074/jbc.M112.375907Ryan KK, Tremaroli V, Clemmensen C, et al. FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature. 2014;509(7499):183-188. DOI:10.1038/nature13135Ryan KK, Tremaroli V, Clemmensen C, et al. FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature. 2014;509(7499):183-188. DOI:10.1038/nature13135Trauner M, Claudel T, Fickert P, et al. Bile Acids as Regulators of Hepatic Lipid and Glucose Metabolism. Dig Dis. 2010;28(1):220-224. DOI:10.1159/000282091Trauner M, Claudel T, Fickert P, et al. Bile Acids as Regulators of Hepatic Lipid and Glucose Metabolism. Dig Dis. 2010;28(1):220-224. DOI:10.1159/000282091Jiang ZG, Robson SC, Yao Z. Lipoprotein metabolism in nonalcoholic fatty liver disease. J Biomed Res. 2013;27(1):1-13.Jiang ZG, Robson SC, Yao Z. Lipoprotein metabolism in nonalcoholic fatty liver disease. J Biomed Res. 2013;27(1):1-13.Li X, Li Y, Yang W, et al. SREBP-1c overexpression induces triglycerides accumulation through increasing lipid synthesis and decreasing lipid oxidation and VLDL assembly in bovine hepatocytes. J Steroid Biochem Mol Biol. 2014;143(1):174-182. DOI:10.1016/j.jsbmb.2014.02.009Li X, Li Y, Yang W, et al. SREBP-1c overexpression induces triglycerides accumulation through increasing lipid synthesis and decreasing lipid oxidation and VLDL assembly in bovine hepatocytes. J Steroid Biochem Mol Biol. 2014;143(1):174-182. DOI:10.1016/j.jsbmb.2014.02.009Lambert G, Amar MJA, Guo G, et al. The Farnesoid X-receptor Is an Essential Regulator of Cholesterol Homeostasis. J Biol Chem. 2003;278(4):2563-2570. DOI:10.1074/jbc.M209525200Lambert G, Amar MJA, Guo G, et al. The Farnesoid X-receptor Is an Essential Regulator of Cholesterol Homeostasis. J Biol Chem. 2003;278(4):2563-2570. DOI:10.1074/jbc.M209525200Seo JA, Kim NH. Fibroblast Growth Factor 21: A Novel Metabolic Regulator. Diabetes Metab J. 2012;36(1):26. DOI:10.4093/dmj.2012.36.1.26Seo JA, Kim NH. Fibroblast Growth Factor 21: A Novel Metabolic Regulator. Diabetes Metab J. 2012;36(1):26. DOI:10.4093/dmj.2012.36.1.26Yao J. FXR agonist GW4064 alleviates endotoxin-induced hepatic inflammation by repressing macrophage activation. World J Gastroenterol. 2014;20(39):14430. DOI:10.3748/wjg.v20.i39.14430Yao J. FXR agonist GW4064 alleviates endotoxin-induced hepatic inflammation by repressing macrophage activation. World J Gastroenterol. 2014;20(39):14430. DOI:10.3748/wjg.v20.i39.14430Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385(9972):956-965. DOI:10.1016/S0140-6736(14)61933-4Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385(9972):956-965. DOI:10.1016/S0140-6736(14)61933-4Mudaliar S, Henry RR, Sanyal AJ, et al. Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease. Gastroenterology. 2013;145(3):574-582.e1. DOI:10.1053/j.gastro.2013.05.042Mudaliar S, Henry RR, Sanyal AJ, et al. Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease. Gastroenterology. 2013;145(3):574-582.e1. DOI:10.1053/j.gastro.2013.05.042Singh AB, Dong B, Kraemer FB, et al. Farnesoid X Receptor Activation by Obeticholic Acid Elevates Liver Low-Density Lipoprotein Receptor Expression by mRNA Stabilization and Reduces Plasma Low-Density Lipoprotein Cholesterol in Mice. Arterioscler Thromb Vasc Biol. 2018;38(10):2448-2459. DOI:10.1161/ATVBAHA.118.311122Singh AB, Dong B, Kraemer FB, et al. Farnesoid X Receptor Activation by Obeticholic Acid Elevates Liver Low-Density Lipoprotein Receptor Expression by mRNA Stabilization and Reduces Plasma Low-Density Lipoprotein Cholesterol in Mice. Arterioscler Thromb Vasc Biol. 2018;38(10):2448-2459. DOI:10.1161/ATVBAHA.118.311122

The authors declare that there are no conflicts of interest present.